Fig. 1.

Median and IQR changes from baseline to week 14/16 and 24 in haemoglobin levels (g/dl).

For patients with anaemia at baseline (A and B), patients with anaemia of mixed aetiology (ferritin ≥15 ng/ml and <60 ng/ml) at baseline (C and D) and patients with anaemia of inflammation (ferritin ≥60 ng/ml) at baseline (E and F). Data for patients who received golimumab or placebo are shown for all studies, the three RA studies combined and the PsA and AS studies separately. *P < 0.05, **P < 0.01, †P < 0.001 using an analysis of variance on the van der Waerden normal scores.